1 in 5 Patients Report Skin Toxicity With Melanoma Rx
In patients with advanced melanoma, nivolumab/relatlimab combination therapy shows a cutaneous irAEs prevalence of 21.5%, with rash and maculopapular eruption being most common.
Medscape Medical News
source https://www.medscape.com/viewarticle/1-5-patients-experience-skin-toxicity-nivolumab-relatlimab-2025a10005ab?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/1-5-patients-experience-skin-toxicity-nivolumab-relatlimab-2025a10005ab?src=rss
Comments
Post a Comment